Search Within

Gunjan Lalitchandra Shah

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (45)
  2. Journal Article (20)
  3. Research Letter (3)
Groups
  1. Advanced Practice Providers (68)
  2. Bone Marrow Transplant (68)
  3. Center for Hematologic Malignancies (68)
  4. Department of Medicine (68)
  5. Hematologic Malignancies, Division of (68)
  6. Survivorship Research (68)

More Groups

People
  1. Sergio Giralt (52)
  2. Miguel-Angel Perales (39)
  3. Sean Devlin (39)
  4. Michael Scordo (38)
  5. Craig Sauter (30)
  6. Parastoo Dahi (27)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (7)
  4. 2021 (9)
  5. 2020 (12)
  6. 2019 (13)

More Years

Publications
  1. Blood (28)
  2. Biology of Blood and Marrow Transplantation (13)
  3. Blood Advances (5)
  4. Bone Marrow Transplantation (4)
  5. Transplantation and Cellular Therapy (4)
  6. Clinical Lymphoma, Myeloma and Leukemia (2)

More Publications

Publishers
  1. American Society of Hematology (33)
  2. Elsevier Inc. (19)
  3. Nature Publishing Group (4)
  4. Taylor & Francis Group (2)
  5. Adis International Ltd (1)
  6. American Association for Cancer Research (1)

More Publishers

Results (68)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Journal Article

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy
    Journal Article

    Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation
    Research Letter

    Lin, R. J.; Baser, R. E.; Elko, T. A.; Korc-Grodzicki, B.; Shahrokni, A.; Maloy, M. A.; Young, J. W.; Tamari, R.; Shah, G. L.; Shaffer, B. C.; more...
    Bone Marrow Transplantation (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • International prognostic index predicts outcomes in patients with relapsed and refractory large diffuse B cell lymphoma treated with commercial CAR T cells
    Meeting Abstract

    Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Roni, S.; Batlevi, Y.; Silverberg, M. L.; Batlevi, C. W.; Brentjens, R.; more...
    Bone Marrow Transplantation (2020)

    Fulltext@MSK | Save